Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15026682 | 0.92 | CYP3A4 (0.61) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL15026696 | 0.87 | CYP3A4 (0.55) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL5852063 | 0.86 | TSHR (0.43) | CYP3A4TSHRHPGDSMN1; SMN2CYP4F2 | |
| SCHEMBL15026698 | 0.83 | CYP3A4 (0.50) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL16174063 | 0.83 | TSHR (0.45) | CYP3A4TSHRCYP4F2CYP4A11 | |
| SCHEMBL3807287 | 0.81 | CES2 (0.48) | CYP4F2CYP4A11 | |
| SCHEMBL15026680 | 0.79 | CYP3A4 (0.61) | CYP3A4TSHRHPGDSMN1; SMN2LPAR3 | |
| SCHEMBL15012487 | 0.79 | CETP (0.44) | TSHRCYP4F2CYP4A11 | |
| Bicarbonate SCHEMBL28559959 | 0.78 | CYP3A4 (0.81) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| Bicarbonate SCHEMBL28241382 | 0.78 | CYP3A4 (0.81) | CYP3A4TSHRLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046576-A1 | NOVEL PYRROLE DERIVATIVES | UNIV LEICESTER (GB) | 2016-02-18 | — | — | US | disclosed |
| US-9221756-B2 | Pyrrole derivatives | UNIVERSITY OF LEICESTER (GB) | 2015-12-29 | — | — | US | disclosed |
| US-20140309193-A1 | NOVEL PYRROLE DERIVATIVES | UNIVERSITY OF LEICESTER (GB) | 2014-10-16 | — | — | US | disclosed |
| WO-2013083975-A2 | NOVEL PYRROLE DERIVATIVES | UNIVERSITY OF LEICESTER (GB) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046576-A1 | NOVEL PYRROLE DERIVATIVES | PYCR1, ARG1, PNISR | CYP3A4 1505/4885TSHR 598/4885HPGD 1394/4885 |
| US-20140309193-A1 | NOVEL PYRROLE DERIVATIVES | PYCR1, ARG1, PNISR | CYP3A4 1505/4885TSHR 598/4885HPGD 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.